EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance

Jing Zhang, Muhammad Tufail, Yun Deng, Hong-Jian Ling, Lin Peng, Jundong Wu, De Zeng, Yongqu Zhang, Lifang He, Hanwei Peng, Abdulloev Afzal, Yan Sun und 2 weitere

Drug Resistance Updates · 2026-09 · 88 · 101432

DOI: 10.1016/j.drup.2026.101432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-09. Verfasst von Jing Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Center, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics, Cancer Hospital of Sh…. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Histidine, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Shantou University Medical College, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly ADP-ribose polymerase inhibitor (PARPi) has shown promising clinical efficacy in patients with BRCA-deficient breast cancer. However, the role of metabolic reprogramming in PARPi resistance remains poorly understood. In this study, we analyzed the amino acid metabolome in samples with varying sensitivity to PARPi, revealing histidine as the most prominently dysregulated amino acid. Disruption of histidine metabolism reprogramming using liposomes containing histidine (Liposome His) effectively resensitized PARPi-resistant cells to olaparib. Mechanistically, Liposome His treatment depleted the tetrahydrofolate (THF) pool, thereby impairing nucleotide synthesis, which was particularly cytotoxic in cells with limited THF availability. Methotrexate and folate depletion further enhanced the in vitro efficacy of Liposome His. In contrast, the folate receptor antagonist mirvetuximab soravtansine exhibited potent anti-proliferative effects against PARPi-resistant cells in vivo, albeit with notable adverse effects. Combination therapy involving Liposome His and mirvetuximab soravtansine demonstrated promising inhibitory effects with manageable tolerability profiles. In addition, we preliminarily demonstrated that Liposome His regulates macrophage polarization by activating the mTOR signaling pathway, and when combined with anti-PD-L1 therapy, it jointly inhibits the pro-tumor phenotype of macrophages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug Resistance, NeoplasmHistidinePoly(ADP-ribose) Polymerase InhibitorsAnimalsFemaleHumansCell Line, TumorLiposomesMetabolic ReprogrammingPiperazinesSignal TransductionPhthalazines

Stichwörter der Autor:innen

Breast cancerHistidine metabolismLiposomeMacrophagePARPi resistance

Substanzen

HistidineLiposomesolaparibPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPhthalazines

Autor:innen und Institutionen

  • Department of Breast Center, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, PR China.
  • Department of Stomatology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, PR China.
  • Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
  • Department of Central Laboratory, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, PR China.
  • Department of Head and Neck Surgery, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, PR China.
  • Department Oral Maxillofacial Surgery, Samarkand State Medical University, Uzbekistan.

Förderung

  • National Key Research and Development Program of China
  • Shantou University Medical College
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, J., Tufail, M., Deng, Y., Ling, H. J., Peng, L., Wu, J., Zeng, Zhang, Y., He, L., Peng, H., Afzal, A., Sun, Y., Gao, X., & Li, J. (2026). Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance. Drug Resistance Updates, 88, 101432. https://doi.org/10.1016/j.drup.2026.101432

Vancouver

Zhang J, Tufail M, Deng Y, Ling HJ, Peng L, Wu J, et al. Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance. Drug Resistance Updates. 2026;88:101432. doi:10.1016/j.drup.2026.101432

BibTeX
@article{Zhang2026,
  author = {Zhang, Jing and Tufail, Muhammad and Deng, Yun and Ling, Hong-Jian and Peng, Lin and Wu, Jundong and Zeng, De and Zhang, Yongqu and He, Lifang and Peng, Hanwei and Afzal, Abdulloev and Sun, Yan and Gao, Xinya and Li, Jie},
  title = {Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {88},
  pages = {101432},
  doi = {10.1016/j.drup.2026.101432}
}
Kostenlos starten →